Compare Abeona Therapeutics Inc (ABEO) vs Align Technology, Inc. (ALGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Align Technology, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Align Technology, Inc. trades at $176.02 (market cap $13.27B). The key difference: Align Technology, Inc. is far larger — about 35.5× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | ALGN | |
|---|---|---|
Market Cap | $373.32M | $13.27B |
Sector | Health | Health |
52-Week High | $7.23 | $207.19 |
52-Week Low | $4.17 | $124.88 |
Enterprise Value | $228.22M | $12.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ALGN trades at $185.22, up 0.38% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Revenue remains stable around $4.0B, supported by a 67.57% gross margin and positive cash flow trends. Recent news highlights global expansion and product innovation, including a new manufacturing facility in India.
Outlook is positive with a $220.75 consensus price target, though risks include regulatory scrutiny from the European Commission and competitive pressures. The stock's valuation at a P/E of 31.65 reflects growth expectations, but investors should monitor execution on international growth and demand stability in North America.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →
